RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE

MILAN, Italy and BUDAPEST, Hungary, Aug. 2, 2016 (GLOBE NEWSWIRE) -- Recordati and Gedeon Richter today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, in Tunisia and in Turkey.

Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product was launched in the USA in March 2016 under the trademark of VRAYLAR TM for the treatment of both bipolar mania and schizophrenia. The European Medicines Agency (EMA) started the evaluation of Richter's marketing authorisation application for cariprazine for the treatment of schizophrenia in March 2016.

Under the terms of the agreement Recordati shall make an upfront payment upon signature of the contract, and further milestone payments shall be made depending on the progress of both the regulatory procedure and the commercialization of the product. In addition, further sales related royalties will become payable to Richter following the launch of the product.

In line with the agreement Richter shall be responsible for conducting Pediatric Clinical Studies according to the Pediatric Investigation Plan, as required by the European Medicines Agency's PDCO (Paediatric Committee) and it shall be co-financed with Recordati.

"We are pleased having Recordati as our marketing partner in Western-Europe, given our long standing relationship and their approach of successfully managing the company for many decades. Their experience and well established international sales network are reflected in a proven track record of introducing successfully new products on the markets. This partnership is aligned with Richter's strategy to bring cariprazine to the market for the millions of people living with schizophrenia and who are seeking an effective new treatment option", stated Erik Bogsch, Managing Director of Gedeon Richter Plc.

"We are very pleased with the addition of this innovative treatment for schizophrenia to our corporate pipeline", stated Giovanni Recordati, Chairman and CEO. "The central nervous system therapeutic sector represents a further area of growth for the group. We believe that the overall high quality of our sales organization together with specific experience matured in some countries in the area of mental health will enable us to create the necessary awareness in our territories for the adoption of this important new treatment for schizophrenia, a serious invalidating mental condition."

About Schizophrenia Schizophrenia is a chronic and disabling disorder that has a worldwide prevalence approaching 1%. It imposes significant burden on patients, their families, and society. Symptoms fall into three broad categories: positive symptoms (hallucinations, delusions, thought disorders, and movement disorders), negative symptoms (such as loss of motivation and social withdrawal), and cognitive symptoms (problems with executive functioning, focusing, and working memory).

About cariprazine Cariprazine is an orally active and potent dopamine D 3 /D 2 receptor partial agonist with preferential binding to D 3 receptors and partial agonist at serotonin 5-HT 1A receptors. Cariprazine was discovered by Richter, having been developed for the treatment of bipolar mania and schizophrenia jointly by Allergan (earlier Forest / Actavis) and Richter and was approved by FDA in both indications in 2015. Currently it is under development by Richter in the EU for the treatment of schizophrenia and for the treatment of schizophrenia with predominant negative symptoms while ongoing clinical developments of cariprazine are being managed by Allergan (earlier Forest / Actavis) and Richter for bipolar depression (BD) and as adjunctive therapy for major depressive disorder (MDD) in the US. Additionally, Mitsubishi-Tanabe Pharma Corporation (MTPC) is developing cariprazine for the treatment of schizophrenia in Japan and in other Asian countries.

Gedeon Richter Plc . ( www.richter.hu ), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Having reached a market capitalisation of EUR 3.3 billion (US$ 3.6 billion) by the end of 2015, Richter's consolidated sales were approximately EUR 1.2 billion (US$ 1.3 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

RICHTER: Investors: Katalin Ördög:             +36 1 431 5680 Media: Zsuzsa Beke:                    +36 1 431 4888

Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America.  An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases.  Consolidated revenue for 2015 was € 1,047.7 million, operating income was € 278.5 million and net income was € 198.8 million.

For further information:

Recordati website:  www.recordati.com

Investor Relations                                                                       Media Relations                     Marianne Tatschke                                                                     Studio Noris Morano                                                            (39)0248787393                                                                          (39)0276004736, (39)0276004745 e-mail: inver@recordati.it                                                          e-mail: norismorano@studionorismorano.com                                                  

S tatements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

Cariprazine license joint release http://hugin.info/143644/R/2032462/756602.pdf

HUG#2032462

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 0

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 18

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 358

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading

Top 5 Most Recently Viewed Articles

CNO Financial's Community Push: Volunteer Recognition & Donations

Updated Category News Views 235

Community Engagement is Front and Center Nothing ticks me off more than a company shying away from its community roots, ya know? But CNO Financial Group (NYSE:CNO) just flipped the script with their latest moves. They recently honored Stacy Muentzer Oakey as Volunteer of the Year and announced an impressive $180,000 in donations to 12 nonprofits under their Invested in...

Continue Reading
Centerspace Sets Date for Q2 2025 Earnings Conference

Updated Category News Views 162

Centerspace Announces Earnings Release Scheduled Centerspace (NYSE: CSR) is preparing to unveil its operating results for the quarter concluding on June 30, 2025. This announcement is set to take place after the market closes, marking a significant event for investors and stakeholders. Conference Call Details A conference call is lined up for interested parties to delve...

Continue Reading
EisnerAmper Achieves Client Satisfaction Excellence Again

Updated Category News Views 66

EisnerAmper Achieves Client Satisfaction Excellence Again EisnerAmper, a global leader in accounting, tax, and advisory services, has been recognized for its exceptional client service by earning the ClearlyRated's "Best of Accounting 5-Year Diamond Award". This prestigious accolade signifies that EisnerAmper has maintained its excellence in client satisfaction for eight...

Continue Reading
Transforming $1000 Investment into a Remarkable $90,000 Gain

Updated Category News Views 248

Transforming a Small Investment into Major Returns Investing in stocks can be a game changer for many individuals, offering opportunities for significant wealth creation over time. One standout example is Fair Isaac Corporation, identified by its ticker FICO. Over the past 15 years, FICO has demonstrated exceptional market performance, surpassing the average market growth...

Continue Reading
Key Insights on How to Identify Lucrative Insider Trades

Updated Category News Views 125

Understanding the Significance of Insider Trades In today's market, finding insider trades that consistently outperform the market can be a game changer for investors. By focusing on insider buying, particularly from C-suite executives, investors can gain valuable insights into companies' future profitability. Profile of Impactful Insiders: C-Suite Executives C-suite...

Continue Reading